Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of a Post-transplantation Switch From Cyclosporin to Tacrolimus Sustained-release Capsules in Renal Transplant Recipients: A Multi-center, Open-label, Uncontrolled Study

NCT02706678 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.

NCT NCT02706678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02706678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of a Post-transplantation Switch From Cyclosporin to Tacrolimus Sustained-release Capsules in Renal Transplant Recipients: A Multi-center, Open-label, Uncontrolled Study
Lead sponsor
Astellas Pharma China, Inc.
Phase
Phase 4
Overall status
Completed
Start date
December 29, 2010
Completion date
August 1, 2012
Enrollment
105 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplant recipients